Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Income from Continuing Operations (2024 - 2025)

Evommune (EVMN) has disclosed Income from Continuing Operations for 2 consecutive years, with 28273000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 36.41% to 28273000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 77390000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 77798000.0 for FY2025, 16.45% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 28273000.0 at Evommune, down from 12475000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 12475000.0 in Q3 2025, with the low at 28273000.0 in Q4 2025.